Imis Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Imis Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, growt…

1981-06-25 Vijayawada (Urban), Andhra Pradesh Active Unlisted Active Compliant
Share
Connect MCP
IP Imis Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Imis Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
87/100
Trust Score
Low Risk

Imis Pharmaceuticals Private Limited is assessed as Low Risk with a Trust Score of 87/100. Imis Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 1981, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 12 Oct 2026 from the latest processed filings. Imis Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
87/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
74/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
85/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 85/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Moderate gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 1 open (2.76 cr) · 8 satisfied (1.13 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Indian Overseas Bank1 48.0 cr
Andhra Bank8 48.0 cr
Compliance Score: 74/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2025).
  • Litigation present in 2 court forum(s).
  • 3 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
NAGA LAKSHMI VEPAKOMMA 01234567 Director 01/04/2018 6 yrs Approved
NAGAMALLIKA GUDIPATY 01234567 Director 01/04/2018 6 yrs Approved
NAGAPRASUNA BALANTRAPU 01234567 Director 01/04/2018 6 yrs Approved
DUBAGUNTA NAGASAILA 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2022)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2022 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: NAGA LAKSHMI VEPAKOMMA (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 85 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Asset base grew 0.86 - capacity expansion.
Operating for 45+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 61% in a year.
1 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence80/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment85/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 2.76 cr already registered.
  • Compliance record supports lending.
Investor view89/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
22 Aug 2020
Director ceased
NAGA LAKSHMI VEPAKOMMA
13 Jan 2019
Director ceased
KRISHNA VEPAKOMMA
19 May 2018
Securities allotted
515 Equity Shares - 23.33 Lakh raised
Securities allotted
485 Equity Shares - 4.85 Lakh raised
04 Aug 2017
Director appointed
NAGAPRASUNA BALANTRAPU (Director)
Director ceased
DUBAGUNTA INDUMATHI
12 Jun 2015
Director appointed
NAGAMALLIKA GUDIPATY (Director)
Director appointed
DUBAGUNTA NAGASAILA (Director)
20 Nov 2013
Charge satisfied
Andhra Bank
13 Jul 2010
Director ceased
LAKSHMINARAYANA DUBAGUNTA
15 May 2009
Charge created
Indian Overseas Bank - 2.76 cr
15 Dec 2008
Charge created
Andhra Bank - 30.00 Lakh
20 Jan 2005
Charge created
Andhra Bank - 6.50 Lakh
10

Key Observations

Auto-generated from the data above
Revenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - manageable leverage.
Net worth is positive.
4 active director(s) / partner(s); board looks stable and experienced.
3 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
EAST COAST CONDUCTORS PVT LTD U99999PY1972PTC000114 -
Hadwins Projects Limited U45200TG2006PLC049948 -
Swan Exporters Private Limited U17111TZ1991PTC003402 -
Singha Dairies Private Limited U15209UP1987PTC008686 -
Q.Z. Builders Private Limited U45201UP1997PTC021447 -
Ikc Technology Limited U74140MH2000PLC128504 -
Silver Oaks Health And Tourist Resort Pv T Ltd U55101HP1990PTC010539 -
Indus Orchards Limited U51215DL1997PLC087604 -
K N S Spinners Pvt. Ltd. U17111TN1990PTC019409 -
Suman Paper And Boards Limited U21093GJ1990PLC013555 -
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Imis Pharmaceuticals Private Limited before audits and certifications: compliance score 74/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Imis Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 85/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Imis Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 87/100, distress signals and MSME payment-delay disclosures - know whether Imis Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Imis Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Imis Pharmaceuticals Private Limited an active company?

Imis Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 74/100 (Moderate).

Is Imis Pharmaceuticals Private Limited financially healthy?

Imis Pharmaceuticals Private Limited has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Imis Pharmaceuticals Private Limited?

Its overall Trust Score is 87/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Imis Pharmaceuticals Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Imis Pharmaceuticals Private Limited have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 8 earlier charge(s) stand satisfied.

Is Imis Pharmaceuticals Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2025). Overall compliance score: 74/100 (Moderate).

Is it risky to lend to Imis Pharmaceuticals Private Limited?

Its Credit Risk Score is 85/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.